NASDAQ:ALZN Alzamend Neuro (ALZN) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free ALZN Stock Alerts $0.71 -0.02 (-2.19%) (As of 03:18 PM ET) Add Compare Share Share Today's Range$0.70▼$0.7450-Day Range$0.68▼$1.2052-Week Range$0.65▼$11.91Volume27,238 shsAverage Volume49,898 shsMarket Capitalization$4.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Alzamend Neuro alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Alzamend Neuro Stock (NASDAQ:ALZN)Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Read More ALZN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALZN Stock News HeadlinesApril 26, 2024 | americanbankingnews.comAlzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest UpdateApril 24, 2024 | msn.comAlzamend Neuro And 2 Other Stocks Under $5 Insiders Are BuyingMay 6, 2024 | Stansberry Research (Ad)Do NOT read if you believe in “woke” politicsI have to warn you, however: This CEO of a publicly traded company is not afraid to mince words. Many on Wall Street have refused to work with him.April 17, 2024 | msn.comAlzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42March 26, 2024 | msn.comALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024February 24, 2024 | msn.comAlzamend Neuro (ALZN) Price Target Increased by 25.00% to 25.50February 13, 2024 | realmoney.thestreet.comMaxim gets more bearish on Alzamend Neuro, downgrades sharesFebruary 3, 2024 | msn.comAlzamend Neuro Risks Nasdaq Delisting Over Price DeficiencyMay 6, 2024 | Stansberry Research (Ad)Do NOT read if you believe in “woke” politicsI have to warn you, however: This CEO of a publicly traded company is not afraid to mince words. Many on Wall Street have refused to work with him.December 19, 2023 | markets.businessinsider.comBuy Rating for Alzamend Neuro Amid Promising Alzheimer’s Drug Trials and Market PotentialDecember 18, 2023 | msn.comALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024December 18, 2023 | msn.comALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024December 11, 2023 | finance.yahoo.comAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder PatientsDecember 11, 2023 | finance.yahoo.comEXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next YearNovember 20, 2023 | marketwatch.comAlzamend Neuro Gets FDA Approval for Trial of Depression TreatmentNovember 20, 2023 | msn.comEXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder StudyNovember 20, 2023 | finance.yahoo.comAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder PatientsNovember 16, 2023 | finance.yahoo.comAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price RequirementNovember 13, 2023 | msn.comEXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug CandidateNovember 13, 2023 | finance.yahoo.comAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001November 2, 2023 | msn.comAlzamend Neuro (ALZN) Price Target Increased by 1306.25% to 57.38October 30, 2023 | benzinga.comWhy Alzamend Neuro (ALZN) Stock Is Nosediving TodayOctober 30, 2023 | finance.yahoo.comAlzamend Neuro Announces Reverse Stock SplitOctober 25, 2023 | finance.yahoo.comAlzamend Neuro, Inc. (9ZT0.F)October 23, 2023 | businesswire.comAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001October 2, 2023 | msn.comEXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar DisorderOctober 2, 2023 | finance.yahoo.comAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsSee More Headlines Receive ALZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today5/06/2024Next Earnings (Estimated)7/25/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALZN CUSIPN/A CIK1677077 Webwww.alzamend.com Phone844-722-6303FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.9895) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,880,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-612.26% Return on Assets-255.65% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book1.51Miscellaneous Outstanding Shares6,870,000Free Float3,281,000Market Cap$4.88 million OptionableOptionable Beta0.12 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Stephan Jackman (Age 47)CEO & Director Comp: $434.24kMr. David J. Katzoff (Age 61)Chief Financial Officer Comp: $116.67kMr. Milton Charles Ault III (Age 54)Founder & Vice Chairman Key CompetitorsCingulateNASDAQ:CINGOragenicsNYSE:OGENNexImmuneNASDAQ:NEXISynaptogenixNASDAQ:SNPXLipella PharmaceuticalsNASDAQ:LIPOView All CompetitorsInsidersMilton C Ault IIIBought 1,000 shares on 4/19/2024Total: $690.00 ($0.69/share)Milton C Ault IIIBought 334 shares on 4/1/2024Total: $303.94 ($0.91/share)Milton C Ault IIIBought 5,000 shares on 1/5/2024Total: $5,100.00 ($1.02/share)Milton C Ault IIIBought 500 shares on 12/26/2023Total: $450.00 ($0.90/share)Milton C Ault IIIBought 200 shares on 12/22/2023Total: $184.00 ($0.92/share)View All Insider Transactions ALZN Stock Analysis - Frequently Asked Questions How have ALZN shares performed in 2024? Alzamend Neuro's stock was trading at $0.89 at the start of the year. Since then, ALZN stock has decreased by 21.1% and is now trading at $0.7020. View the best growth stocks for 2024 here. Are investors shorting Alzamend Neuro? Alzamend Neuro saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 14,500 shares, a decrease of 68.0% from the March 31st total of 45,300 shares. Based on an average trading volume of 55,500 shares, the short-interest ratio is currently 0.3 days. Approximately 0.3% of the company's shares are sold short. View Alzamend Neuro's Short Interest. When is Alzamend Neuro's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our ALZN earnings forecast. How were Alzamend Neuro's earnings last quarter? Alzamend Neuro, Inc. (NASDAQ:ALZN) released its quarterly earnings results on Monday, March, 25th. The company reported ($0.38) EPS for the quarter. When did Alzamend Neuro's stock split? Shares of Alzamend Neuro reverse split on the morning of Tuesday, October 31st 2023. The 1-15 reverse split was announced on Tuesday, October 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Alzamend Neuro IPO? Alzamend Neuro (ALZN) raised $12 million in an IPO on Tuesday, June 15th 2021. The company issued 2,500,000 shares at a price of $5.00 per share. Spartan Capital Securities, LLC served as the underwriter for the IPO and -- was co-manager. Who are Alzamend Neuro's major shareholders? Alzamend Neuro's stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David J Katzoff, L Mary Smith, Lynne Fahey Mcgrath, Mark Gustafson, Milton C Ault III, Milton C Ault III, Milton C Ault III and Stephan Jackman. View institutional ownership trends. How do I buy shares of Alzamend Neuro? Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALZN) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsDollar CancelledLear CapitalElon to Transform U.S. Economy? Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin Analytics“Crash Insurance” For Your RetirementUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
